Eli Lilly stated that "anyone continuing to sell mass compounded tirzepatide, including by referring to it as personalized, tailored, or something similar, is breaking the law and deceiving patients." Orderly Meds responded publicly, stating they believed the cease-and-desist was without legal merit and that they intended to continue operations
Prior GLP-1-based medication use The majority of patients (94.2%) had an encounter within the prior year and were therefore included in the switching pattern analysis
Brindisi M-C, Brondel L, Meillon S, Barthet S, Grall S, Fenech C, et al
J Biol Chem 279: 52575262 Chakravarthi S, Bulleid NJ (2004) Glutathione is required to regulate the formation of native disulphide bonds within proteins entering the secretory pathway
patients are unlikely to see an FDA-approved generic semaglutide injection before December 2031 at the earliest